Navigation Links
JCI early table of contents for July 16, 2012
Date:7/16/2012

ONCOLOGY

A new target in acute myeloid leukemia | Back to top

Acute myeloid leukemia, a common leukemia in adults, is characterized by aberrant proliferation of cancerous bone marrow cells. Activating mutations in a protein receptor known as FLT3 receptor are among the most prevalent mutations observed in acute myeloid leukemias. FLT3 mutants are thought to activate several signaling pathways that contribute to cancer development. Dr. Daniel Tenen and colleagues from Harvard University in Boston discovered a new pathway activated by FLT3 mutation. Their results show that cyclin dependent kinase 1 (CDK1), a critical regulator of cell division is activated in FLT3 mutated leukemias, leading to the activation of downstream gene transcription. Most importantly, they demonstrate that inhibiting CDK1 activity promotes differentiation of cells from patient-derived peripheral blood samples. As clinical trials with CDK1 inhibitors are ongoing, their data strongly suggest that therapies targeting the CDK1 pathway may be efficacious for acute myeloid leukemias with FLT3 mutation, especially in patients resistant to FLT3 inhibitor therapies.

TITLE:

Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα

AUTHOR CONTACT:

Daniel Tenen

Beth Israel Deaconess Medical Center, Boston, MA, USA

Phone: 617-735-2235; Fax: 617-735-2222; E-mail: dtenen@bidmc.harvard.edu

View this article at: http://www.jci.org/articles/view/43354?key=65aa2f71faac98dd69ed

ONCOLOGY

A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers | Back to top

Cancer is principally considered a genetic disease, and numerous mutations are thought essential to drive its growth. However, the existence of genomically stable cancers raises the possibility that changes in few genes that regulate chromatin structure and gene expression are capable of driving cancer formation. Dr. Charles Roberts and colleauges at the Dana-Farber Cancer Institute in Boston sequenced the expressed genes of rhabdoid tumors, highly aggressive cancers of early childhood. These tumors typically exhibit loss of a protein known as SMARCB1, a subunit of the chromatin remodeling complex that is important in controlling gene transcription. The Roberts group identified an extremely low rate of mutations, with loss of SMARCB1 as the only recurrent event. Their results demonstrate that high mutation rates are typically associated with cancer development is not required in all tumors, particularly for cancers driven by mutation of a chromatin remodeling complex. Thus, remarkably simple genetic changes can underlie cancer development.

TITLE:

A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers

AUTHOR CONTACT:

Charles Roberts

Dana-Farber Cancer Institute, Boston, MA, USA

Phone: 617-632-6497; Fax: 617-582-8096; E-mail: charles_roberts@dfci.harvard.edu

View this article at: http://www.jci.org/articles/view/64400?key=226866e0e308ef85783e

ONCOLOGY

PHD3-dependent hydroxylation of HCLK2 promotes the DNA damage response | Back to top

The DNA damage response (DDR) is a complex regulatory network that is critical for maintaining genome integrity. Posttranslational modifications are widely used to ensure strict spatiotemporal control of signal flow, but how the DDR responds to environmental cues, such as changes in ambient oxygen tension, remains poorly understood. Cam Patterson and colleagues at the University of North Carolina found that an essential component of the ATR/CHK1 signaling pathway, known as HCLK2, associated with and was hydroxylated by prolyl hydroxylase domain protein 3 (PHD3). HCLK2 hydroxylation was necessary for its interaction with ATR and the subsequent activation of the DDR. Inhibiting PHD3 prevented activation of the ATR/CHK1/p53 pathway and decreased cell death induced by DNA damage. Consistent with these observations, they found that mice lacking PHD3 were resistant to the effects of ionizing radiation and had decreased thymic apoptosis, a biomarker of genomic integrity.

TITLE:

PHD3-dependent hydroxylation of HCLK2 promotes the DNA damage response

AUTHOR CONTACT:

Cam Patterson

University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Phone: 919-843-6477; Fax: 9198434585; E-mail: cpatters@med.unc.edu

View this article at: http://www.jci.org/articles/view/62374?key=2f34187c2dec70f6cd0e

OPHTHALMOLOGY

Inflammation and age−related retinal degeneration | Back to top

Disruption of cellular processes affected by multiple genes and accumulation of numerous insults throughout life dictate the progression of age−related disorders, but their complex etiology is poorly understood. Post−mitotic neurons, such as photoreceptor cells in the retina, and the adjacent retinal pigmented epithelium that together maintain vision, are especially susceptible to age−related retinal degeneration (ARD). The multi-genic etiology of ARD in humans is reflected by the relative paucity of effective compounds for its early prevention and treatment. To understand the background genetic differences that drive the phenotypic progression of ARD, Dr. Krzysztof Palczewski and colleagues at Case Western University in Cleveland, OH studied a strain of mice that develop more pronounced ARD than other inbred mouse models. Using state-of-the-art genetic analysis, they identified several genetic changes that cause an increased predisposition to ARD in mice. These insights may further improve our understanding of susceptible genetic loci that drive disease involved in age−associated disorders, including several human blinding diseases.

TITLE:

Inflammatory priming predisposes to age−related retinal degeneration in mice

AUTHOR CONTACT:

Krzysztof Palczewski

Case Western Reserve University, Cleveland, OH, USA

Phone: 216-368-4631; E-mail: kxp65@case.edu

View this article at: http://www.jci.org/articles/view/64427?key=226400a103c96592270a


'/>"/>
Contact: Sarah Jackson
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Related medicine news :

1. New Stool Test Might Aid in Early Detection of Colon Cancer
2. An Early Start for Your Child with Autism
3. Early Study Finds Some Promise for Lung Cancer Vaccine
4. Treat Rheumatoid Arthritis Early and Aggressively: Guidelines
5. JCI early table of contents for April 9, 2012
6. Eye Tremors May Aid Early Diagnosis of Parkinsons: Study
7. Nearly 1 in 4 grandparents store prescription medicines where children can easily find them
8. First contact: Early intervention key in diagnosis and treatment of serious mental illness
9. Brain Tumor Vaccine Shows Promise in Early Trial
10. Role of Screening, Monitoring in Early Kidney Disease Unclear
11. Detecting malaria early to save lives: New optical technique promises rapid and accurate diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical ... be the preferred physical therapy provider for Derby City CrossFit, effective immediately. , ... CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will work ...
(Date:4/25/2017)... ... 25, 2017 , ... A recent report from the Wisconsin ... the 2015-16 school year across Wisconsin’s public schools, charter schools, and private schools ... in student test score performance, the report’s limited analyses fail to provide answers ...
(Date:4/25/2017)... ... 25, 2017 , ... As pharmaceutical companies are held to ... process innovation in drug formulation and manufacturing. CoreRx offers its clients more ... in support of their development and manufacturing goals. , The company was ...
(Date:4/25/2017)... ... ... MD is committed to providing the highest quality of spine care to all his patients. ... all my patients to alleviate possible future issues. I am pleased to have you as ... my trained staff will assist you in any way possible.” , Dr. Saad Chaudhary is ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , ... Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day ... at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
Breaking Medicine Technology: